TY - JOUR
T1 - NPS MedicineWise application in supporting medication adherence in chronic heart failure
T2 - an acceptability and feasibility pilot study
AU - Chapman-Goetz, Jessica
AU - Packham, Nerida
AU - Yu, Kitty
AU - Gabb, Genevieve
AU - Potts, Cassandra
AU - Prosser, Adaire
AU - Arstall, Margaret A.
AU - Burdeniuk, Christine
AU - Chan, Alicia
AU - Wilson, Teena
AU - Hotham, Elizabeth
AU - Suppiah, Vijayaprakash
N1 - Funding Information:
Funding for this study was independently provided to NPS MedicineWise and the University of South Australia by the Innovation Connections Grant scheme by the Department of Industry, Innovation and Science and NPS VentureWise Pty Ltd. (grant no. ICG000775 and ICG000776). NPS MedicineWise would like to acknowledge funding from the Australian Government Department of Health to develop and maintain the MedicineWise app. JC-G was supported by the Australian Government Research Training Program (RTP) fee offset scholarship to conduct this research as part of her Masters by Research degree at the University of South Australia. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. Acknowledgments
Publisher Copyright:
2023 Chapman-Goetz, Packham, Yu, Gabb, Potts, Prosser, Arstall, Burdeniuk, Chan, Wilson, Hotham and Suppiah.
PY - 2023
Y1 - 2023
N2 - Introduction: Heart failure (HF) is an increasing global concern. Despite evidence-based pharmacotherapy, associated morbidity and mortality remain high. This study aimed to assess the acceptability, feasibility, and value of the NPS MedicineWise dose reminder app in a tiered, pharmacist-led intervention to address medication non-adherence in patients with HF. Methods: This prospective, single-blinded, randomised controlled trial recruited 55 patients with HF between September 2019 and October 2020. Participants were randomly assigned to either the intervention or control arms. Intervention participants used the app which prompted medication administration at each dosing interval. Control participants received standard care and remained blinded to the app throughout the study. Treatment non-adherence prompted a tiered, pharmacist-led intervention. Comparison of the Self-Efficacy for Appropriate Medication Use Scale (SEAMS) at baseline and 6-months measured the app's value in supporting medication adherence. Secondary outcome measures included self-reported medication knowledge, health-related quality of life, psychological wellbeing, and signs and symptoms of HF. Data were analysed using standard statistical tests with significance set at α 0.05. Results: Approximately half of respondents reported managing HF and medications better by using the MedicineWise app (Tier 1). Most respondents expressed satisfaction with the in-app messages (Tier 2) and pharmacists' phone calls (Tier 3). The intervention participants demonstrated a significant improvement in the SEAMS between baseline and 6-months follow-up. Discussion: It is feasible and potentially of value to use the MedicineWise app with a tiered, pharmacist-led intervention to support medication adherence in patients with HF. Our findings provide clinicians with “real-world” information on the practicality and potential value of using mobile health to support treatment adherence in patients with HF. Trial registration number: Australian New Zealand Clinical Trials Registry Clinical trial registration number: ACTRN12619000289112p (http://www.ANZCTR.org.au/ACTRN12619000289112p.aspx).
AB - Introduction: Heart failure (HF) is an increasing global concern. Despite evidence-based pharmacotherapy, associated morbidity and mortality remain high. This study aimed to assess the acceptability, feasibility, and value of the NPS MedicineWise dose reminder app in a tiered, pharmacist-led intervention to address medication non-adherence in patients with HF. Methods: This prospective, single-blinded, randomised controlled trial recruited 55 patients with HF between September 2019 and October 2020. Participants were randomly assigned to either the intervention or control arms. Intervention participants used the app which prompted medication administration at each dosing interval. Control participants received standard care and remained blinded to the app throughout the study. Treatment non-adherence prompted a tiered, pharmacist-led intervention. Comparison of the Self-Efficacy for Appropriate Medication Use Scale (SEAMS) at baseline and 6-months measured the app's value in supporting medication adherence. Secondary outcome measures included self-reported medication knowledge, health-related quality of life, psychological wellbeing, and signs and symptoms of HF. Data were analysed using standard statistical tests with significance set at α 0.05. Results: Approximately half of respondents reported managing HF and medications better by using the MedicineWise app (Tier 1). Most respondents expressed satisfaction with the in-app messages (Tier 2) and pharmacists' phone calls (Tier 3). The intervention participants demonstrated a significant improvement in the SEAMS between baseline and 6-months follow-up. Discussion: It is feasible and potentially of value to use the MedicineWise app with a tiered, pharmacist-led intervention to support medication adherence in patients with HF. Our findings provide clinicians with “real-world” information on the practicality and potential value of using mobile health to support treatment adherence in patients with HF. Trial registration number: Australian New Zealand Clinical Trials Registry Clinical trial registration number: ACTRN12619000289112p (http://www.ANZCTR.org.au/ACTRN12619000289112p.aspx).
KW - heart failure
KW - medication adherence
KW - mobile health (mHealth)
KW - mobile phone application
KW - mobile technology
UR - http://www.scopus.com/inward/record.url?scp=85178204099&partnerID=8YFLogxK
U2 - 10.3389/fdgth.2023.1274355
DO - 10.3389/fdgth.2023.1274355
M3 - Article
AN - SCOPUS:85178204099
SN - 2673-253X
VL - 5
JO - Frontiers in Digital Health
JF - Frontiers in Digital Health
M1 - 1274355
ER -